AbCellera Biologics (ABCL) Return on Sales (2020 - 2024)
Historic Return on Sales for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2024 value amounting to 5.14%.
- AbCellera Biologics' Return on Sales fell 8000.0% to 5.14% in Q3 2024 from the same period last year, while for Sep 2024 it was 5.14%, marking a year-over-year decrease of 25700.0%. This contributed to the annual value of 5.65% for FY2024, which is 18000.0% down from last year.
- Latest data reveals that AbCellera Biologics reported Return on Sales of 5.14% as of Q3 2024, which was down 8000.0% from 4.8% recorded in Q2 2024.
- Over the past 5 years, AbCellera Biologics' Return on Sales peaked at 0.78% during Q4 2020, and registered a low of 5.14% during Q4 2023.
- Moreover, its 5-year median value for Return on Sales was 0.45% (2020), whereas its average is 1.73%.
- As far as peak fluctuations go, AbCellera Biologics' Return on Sales soared by 41400bps in 2022, and later plummeted by -46000bps in 2023.
- Quarter analysis of 5 years shows AbCellera Biologics' Return on Sales stood at 0.78% in 2020, then plummeted by -44bps to 0.43% in 2021, then crashed by -422bps to 1.39% in 2022, then plummeted by -270bps to 5.14% in 2023, then changed by 0bps to 5.14% in 2024.
- Its Return on Sales stands at 5.14% for Q3 2024, versus 4.8% for Q2 2024 and 4.11% for Q1 2024.